Q&A: Poolbeg Pharma on target for $1bn cancer opportunity
Vox Markets talks to (POLB ) CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy.
0:30 How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS
1:36 The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting
3:12 How an Independent Advisory Board is supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS.
5:02 Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.